Australia's Acrux soars on US FDA approval for acne treatment gel

Acrux

27/08/2024 04:12

** Shares of Acrux  ACR.AX  soar as much as 31.7% to A$0.079
- their highest levels since mid-June
    ** Specialty pharma co receives U.S. FDA nod for its generic
version of Aczone Gel, 7.5%, that is used to treat acne vulgaris
in patients nine years and older
    ** About 4.6 mln shares traded, 20.3 times the 30-day avg
    ** Stock has risen 36.7% this year as of last close

 (Reporting by Archishma Iyer)
 ((Archishma.Iyer@thomsonreuters.com;))